Avivit Cahn1,2, Stephen D Wiviott3, Ofri Mosenzon1,2, Sabina A Murphy3, Erica L Goodrich3, Ilan Yanuv1, Aliza Rozenberg1, John P H Wilding4, Lawrence A Leiter5, Deepak L Bhatt3, Darren K McGuire6, Leon Litwak7, Adriaan Kooy8, Ingrid A M Gause-Nilsson9, Martin Fredriksson9, Anna Maria Langkilde9, Marc S Sabatine3, Itamar Raz1,2. 1. Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel. 2. Faculty of Medicine, Hebrew University of Jerusalem, Israel. 3. Division of Cardiovascular Medicine, TIMI Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 4. Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK. 5. Department of Medicine, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Canada. 6. Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, Texas. 7. Endocrinology Unit, Diabetes Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. 8. University Medical Center Groningen and Bethesda Diabetes Research Center, Groningen, the Netherlands. 9. BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Abstract
AIM: To assess the associations between baseline glucose-lowering agents (GLAs) and cardiorenal outcomes with dapagliflozin versus placebo in the DECLARE-TIMI 58 study. MATERIALS AND METHODS: DECLARE-TIMI 58 assessed the cardiorenal outcomes of dapagliflozin versus placebo in patients with type 2 diabetes. This post hoc analysis elaborates the efficacy and safety outcomes by baseline GLA for treatment effect and GLA-based treatment interaction. RESULTS: At baseline, 14 068 patients (82.0%) used metformin, 7322 (42.7%) sulphonylureas, 2888 (16.8%) dipeptidyl peptidase-4 inhibitors, 750 (4.4%) glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and 7013 (40.9%) insulin. Dapagliflozin reduced the composite of cardiovascular death (CVD) and hospitalization for heart failure (HHF) versus placebo regardless of baseline GLA, with greater benefit in the small group of patients with baseline use of GLP-1 RAs (HR [95% CI] 0.37 [0.18, 0.78] vs. 0.86 [0.75, 0.98] in GLP-1 RA users vs. non-users, Pinteraction = .03). The overall HR for major adverse cardiovascular events (CVD, myocardial infarction or ischaemic stroke) was 0.93 (95% CI 0.84, 1.03) with dapagliflozin versus placebo, with no interaction by baseline GLA (Pinteraction > .05). The renal-specific outcome was reduced with dapagliflozin versus placebo in the overall cohort (HR [95%CI] 0.53[0.43-0.66]), with no interaction by baseline GLA (Pinteraction > .05). All of these outcomes were similar in those with versus those without baseline metformin use. CONCLUSIONS: The effects of dapagliflozin on cardiorenal outcomes were generally consistent regardless of baseline GLA, with consistent benefits regardless of baseline metformin use. The potential clinical benefit of combining sodium-glucose co-transporter-2 inhibitors with GLP-1 RAs, given some evidence of cardiovascular risk reduction with both classes, should be explored further.
AIM: To assess the associations between baseline glucose-lowering agents (GLAs) and cardiorenal outcomes with dapagliflozin versus placebo in the DECLARE-TIMI 58 study. MATERIALS AND METHODS: DECLARE-TIMI 58 assessed the cardiorenal outcomes of dapagliflozin versus placebo in patients with type 2 diabetes. This post hoc analysis elaborates the efficacy and safety outcomes by baseline GLA for treatment effect and GLA-based treatment interaction. RESULTS: At baseline, 14 068 patients (82.0%) used metformin, 7322 (42.7%) sulphonylureas, 2888 (16.8%) dipeptidyl peptidase-4 inhibitors, 750 (4.4%) glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and 7013 (40.9%) insulin. Dapagliflozin reduced the composite of cardiovascular death (CVD) and hospitalization for heart failure (HHF) versus placebo regardless of baseline GLA, with greater benefit in the small group of patients with baseline use of GLP-1 RAs (HR [95% CI] 0.37 [0.18, 0.78] vs. 0.86 [0.75, 0.98] in GLP-1 RA users vs. non-users, Pinteraction = .03). The overall HR for major adverse cardiovascular events (CVD, myocardial infarction or ischaemic stroke) was 0.93 (95% CI 0.84, 1.03) with dapagliflozin versus placebo, with no interaction by baseline GLA (Pinteraction > .05). The renal-specific outcome was reduced with dapagliflozin versus placebo in the overall cohort (HR [95%CI] 0.53[0.43-0.66]), with no interaction by baseline GLA (Pinteraction > .05). All of these outcomes were similar in those with versus those without baseline metformin use. CONCLUSIONS: The effects of dapagliflozin on cardiorenal outcomes were generally consistent regardless of baseline GLA, with consistent benefits regardless of baseline metformin use. The potential clinical benefit of combining sodium-glucose co-transporter-2 inhibitors with GLP-1 RAs, given some evidence of cardiovascular risk reduction with both classes, should be explored further.
Authors: Carlos King Ho Wong; Kristy Tsz Kwan Lau; Eric Ho Man Tang; Chi Ho Lee; Carmen Yu Yan Lee; Yu Cho Woo; Ivan Chi Ho Au; Kathryn Choon Beng Tan; David Tak Wai Lui Journal: Cardiovasc Diabetol Date: 2022-06-03 Impact factor: 8.949
Authors: Brendon L Neuen; Clare Arnott; Vlado Perkovic; Gemma Figtree; Dick de Zeeuw; Greg Fulcher; Min Jun; Meg J Jardine; Sophia Zoungas; Carol Pollock; Kenneth W Mahaffey; Bruce Neal; Hiddo J L Heerspink Journal: Diabetes Obes Metab Date: 2020-10-29 Impact factor: 6.577
Authors: Samuel Dagogo-Jack; Christopher P Cannon; David Z I Cherney; Francesco Cosentino; Jie Liu; Annpey Pong; Ira Gantz; Robert Frederich; James P Mancuso; Richard E Pratley Journal: Diabetes Obes Metab Date: 2022-03-29 Impact factor: 6.408
Authors: Kristy T K Lau; Carlos K H Wong; Ivan C H Au; Wallis C Y Lau; Kenneth K C Man; Celine S L Chui; Ian C K Wong Journal: J Am Heart Assoc Date: 2022-03-24 Impact factor: 6.106